Antibody Therapeutics in Cancer von Sliwkowski, Mark X., Mellman, Ira

Volltext

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells von Li, Guangmin, Guo, Jun, Shen, Ben-Quan, Yadav, Daniela Bumbaca, Sliwkowski, Mark X, Crocker, Lisa M, Lacap, Jennifer A, Phillips, Gail D Lewis

Volltext

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer von LoRusso, Patricia M, Weiss, Denise, Guardino, Ellie, Girish, Sandhya, Sliwkowski, Mark X

Volltext

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer von Junttila, Teemu T., Li, Guangmin, Parsons, Kathryn, Phillips, Gail Lewis, Sliwkowski, Mark X.

Volltext

Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates von Caculitan, Niña G, Dela Cruz Chuh, Josefa, Ma, Yong, Zhang, Donglu, Kozak, Katherine R, Liu, Yichin, Pillow, Thomas H, Sadowsky, Jack, Cheung, Tommy K, Phung, Qui, Haley, Benjamin, Lee, Byoung-Chul, Akita, Robert W, Sliwkowski, Mark X, Polson, Andrew G

Volltext

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 von Junttila, Teemu T., Akita, Robert W., Parsons, Kathryn, Fields, Carter, Lewis Phillips, Gail D., Friedman, Lori S., Sampath, Deepak, Sliwkowski, Mark X.

Volltext

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor von Stamos, Jennifer, Sliwkowski, Mark X, Eigenbrot, Charles

Volltext

Oncogenic ERBB3 Mutations in Human Cancers von Jaiswal, Bijay S., Kljavin, Noelyn M., Stawiski, Eric W., Chan, Emily, Parikh, Chaitali, Durinck, Steffen, Chaudhuri, Subhra, Pujara, Kanan, Guillory, Joseph, Edgar, Kyle A., Janakiraman, Vasantharajan, Scholz, Rolf-Peter, Bowman, Krista K., Lorenzo, Maria, Li, Hong, Wu, Jiansheng, Yuan, Wenlin, Peters, Brock A., Kan, Zhengyan, Stinson, Jeremy, Mak, Michelle, Modrusan, Zora, Eigenbrot, Charles, Firestein, Ron, Stern, Howard M., Rajalingam, Krishnaraj, Schaefer, Gabriele, Merchant, Mark A., Sliwkowski, Mark X., de Sauvage, Frederic J., Seshagiri, Somasekar

Volltext

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates von Shen, Ben-Quan, Xu, Keyang, Liu, Luna, Raab, Helga, Bhakta, Sunil, Kenrick, Margaret, Parsons-Reponte, Kathryn L, Tien, Janet, Yu, Shang-Fan, Mai, Elaine, Li, Dongwei, Tibbitts, Jay, Baudys, Jakub, Saad, Ola M, Scales, Suzie J, McDonald, Paul J, Hass, Philip E, Eigenbrot, Charles, Nguyen, Trung, Solis, Willy A, Fuji, Reina N, Flagella, Kelly M, Patel, Darshana, Spencer, Susan D, Khawli, Leslie A, Ebens, Allen, Wong, Wai Lee, Vandlen, Richard, Kaur, Surinder, Sliwkowski, Mark X, Scheller, Richard H, Polakis, Paul, Junutula, Jagath R

Volltext

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy von Lee-Hoeflich, Si Tuen, Crocker, Lisa, Yao, Evelyn, Pham, Thinh, Munroe, Xander, Hoeflich, Klaus P, Sliwkowski, Mark X, Stern, Howard M

Volltext

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer von KROP, Ian E, BEERAM, Muralidhar, JACOBSON, Fred, LUTZKER, Stuart G, BURRIS, Howard A, MODI, Shanu, JONES, Suzanne F, HOLDEN, Scott N, WEI YU, GIRISH, Sandhya, TIBBITTS, Jay, YI, Joo-Hee, SLIWKOWSKI, Mark X

Volltext

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies von Schaefer, Gabriele, Haber, Lauric, Crocker, Lisa M., Shia, Steven, Shao, Lily, Dowbenko, Donald, Totpal, Klara, Wong, Anne, Lee, Chingwei V., Stawicki, Scott, Clark, Robyn, Fields, Carter, Lewis Phillips, Gail D., Prell, Rodney A., Danilenko, Dimitry M., Franke, Yvonne, Stephan, Jean-Philippe, Hwang, Jiyoung, Wu, Yan, Bostrom, Jenny, Sliwkowski, Mark X., Fuh, Germaine, Eigenbrot, Charles

Volltext

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index von Junutula, Jagath R, Mallet, William, Raab, Helga, Clark, Suzanna, Bhakta, Sunil, Leipold, Douglas D, Weir, Sylvia, Chen, Yvonne, Simpson, Michelle, Tsai, Siao Ping, Dennis, Mark S, Lu, Yanmei, Meng, Y Gloria, Ng, Carl, Yang, Jihong, Lee, Chien C, Duenas, Eileen, Gorrell, Jeffrey, Katta, Viswanatham, Kim, Amy, McDorman, Kevin, Flagella, Kelly, Venook, Rayna, Ross, Sarajane, Spencer, Susan D, Lee Wong, Wai, Lowman, Henry B, Vandlen, Richard, Sliwkowski, Mark X, Scheller, Richard H, Polakis, Paul

Volltext

High cell-surface density of HER2 deforms cell membranes von Chung, Inhee, Reichelt, Mike, Shao, Lily, Akita, Robert W., Koeppen, Hartmut, Rangell, Linda, Schaefer, Gabriele, Mellman, Ira, Sliwkowski, Mark X.

Volltext

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results von Lewis, Gail D., Li, Guangmin, Guo, Jun, Yu, Shang-Fan, Fields, Carter T., Lee, Genee, Zhang, Donglu, Dragovich, Peter S., Pillow, Thomas, Wei, BinQing, Sadowsky, Jack, Leipold, Douglas, Wilson, Tim, Kamath, Amrita, Mamounas, Michael, Lee, M. Violet, Saad, Ola, Choeurng, Voleak, Ungewickell, Alexander, Monemi, Sharareh, Crocker, Lisa, Kalinsky, Kevin, Modi, Shanu, Jung, Kyung Hae, Hamilton, Erika, LoRusso, Patricia, Krop, Ian, Schutten, Melissa M., Commerford, Renee, Sliwkowski, Mark X., Cho, Eunpi

Volltext

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotini... von CAREY, Kendall D, GARTON, Andrew J, ROMERO, Maria S, KAHLER, Jennifer, THOMSON, Stuart, ROSS, Sarajane, PARK, Frances, HALEY, John D, GIBSON, Neil, SLIWKOWSKI, Mark X

Volltext

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab von ADAMS, Camellia W, ALLISON, David E, FLAGELLA, Kelly, PRESTA, Leonard, CLARKE, Janet, DYBDAL, Noel, MCKEEVER, Kathleen, SLIWKOWSKI, Mark X

Volltext

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer von MAKHIJA, Sharmila, AMLER, Lukas C, STRAUSS, Andreas, KELSEY, Stephen, SLIWKOWSKI, Mark X, MATULONIS, Ursula, GLENN, Dana, UELAND, Frederick R, GOLD, Michael A, DIZON, Don S, PATON, Virginia, LIN, Chin-Yu, JANUARIO, Thomas, NG, Kimmie

Volltext

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin von Austin, Cary D, De Mazière, Ann M, Pisacane, Paul I, van Dijk, Suzanne M, Eigenbrot, Charles, Sliwkowski, Mark X, Klumperman, Judith, Scheller, Richard H

Volltext

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth von Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X

Volltext